Sanofi completed a $25m investment in Adagene.

Sanofi, a French multinational pharmaceutical company, completed a $25m investment in Adagene, a biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company plans to use the proceeds to fund its research and development activities, including clinical development of muzastotug , an anti-CTLA-4 SAFEbody, through a randomized phase 2 trial in microsatellite stable colorectal cancer.